← FDA DRUG APPROVALS

FDA ANDA · ANDA206234

SEVELAMER CARBONATE

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA206234
TYPE
ANDA
ORIGINAL APPROVAL
2024-07-12
LATEST ACTION
2024-07-12
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

SEVELAMER CARBONATEDiscontinued
SEVELAMER CARBONATE 800MG/PACKET · FOR SUSPENSION · ORAL
SEVELAMER CARBONATEDiscontinued
SEVELAMER CARBONATE 2.4GM/PACKET · FOR SUSPENSION · ORAL

Approval history

2024-07-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →